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Background: No more than 10-15% of type 2 diabetes mellitus (T2DM) patients achieve all treatment goals regarding
glycaemic control, lipids and blood pressure. Shared decision making (SDM) should increase that percentage; however,
not all support decision tools are appropriate. Because the ADDITION-Europe study demonstrated two (almost)
equally effective treatments but with slightly different intensities, it may be a good starting point to discuss with
the patients their diabetes treatment, taking into account both the intensity of treatment, clinical factors and
patients’ preferences. We aim to evaluate whether such an approach increases the proportion of patients that
achieve all three treatment goals.
Methods: In a cluster-randomised trial including 40 general practices, that participated until 2009 in the ADDITION
Study, 150 T2DM patients 60–80 years, known with T2DM for 8-15 years, will be included. Practices are randomised a
second time, i.e. intervention practices in the ADDITION study could be control practices in the current study and vice
versa. For the GPs from the intervention group a 2-hour training in SDM was developed as well as a decision support
tool to be used during the consultation. GPs plan the first visit with the patients to decide on the intensity of the
treatment, personalised targets and the priorities of treatment. The control group will continue with the treatment
they were allocated to in the ADDITION study. Follow-up: 24 months. The primary outcome is the proportion of
patients who achieve all three treatment goals. Secondary outcomes are the proportion of patients who achieve
five treatment goals (HbA1c, blood pressure, total cholesterol, body weight, not smoking), evaluation of the SDM
process (SDM-Q9 and CPS), satisfaction with the treatment (DTSQ), wellbeing and quality of life (W-BQ12, ADD QoL-19),
health status (SF-36, EQ-5D) and coping (DCMQ). The proportions of achieved treatment goals will be compared between
both groups. For the secondary outcomes mixed models will be used. The Medical Research Ethics Committee of
the University Medical Centre Utrecht has approved the study protocol (Protocol number: 11-153).
Discussion: This trial will provide evidence whether an intervention with a multi-faceted decision support tool
increases the proportion of achieved personalised goals in type 2 diabetes patients.
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Successful prevention of complications in the increasing
number of patients with type 2 diabetes (T2DM) appears
to be difficult. In primary care no more than 10-15% of
the patients with T2DM achieve all three treatment tar-
gets (glycaemic control, lipids, blood pressure) [1-6]. For
separate targets much higher percentages of about 30-
70% are reported [2-6]. Therefore, it has been suggested
that a more personalised and patient centred approach
might increase the proportion of patients who success-
fully reach all their treatment targets [7,8]. To personal-
ise treatment targets for HbA1c, lipids, blood pressure,
weight loss and smoking cessation, several factors have
to be considered in order to encourage active participation
of patients in evidence based clinical decision making.
Physicians are advised to consider the patients’ age,
motivation, risk of hypoglycaemia, diabetes duration, co-
morbidity and established vascular complications in set-
ting the glucose control target [8,9]. For statin therapy,
physicians should consider the patient’s individual chol-
esterol level, his/her risk for cardiovascular mortality,
age and T2DM duration [10]. The blood pressure target
for patients with T2DM is below 140/80 [11,12], but for
older patients a less strict treatment target may result in
a higher survival rate [13]. With regard to weight con-
trol, physicians have to consider the side effects of
weight gain of medication. Intensive lifestyle modification
remains an elusive gold standard for weight reduction [14]
Although smoking cessation has been associated with
weight gain, it is recommended as a routine component of
the treatment of diabetes; however, evidence to guide best
practice is limited [15].
To achieve and maintain treatment targets, not only
individual clinical characteristics should be considered,
but also patients’ preferences for treatment intensity.
Generally speaking, the doctor is the expert on medicine,
while the patient is the expert on his or her priorities
[16]. Shared decision making (SDM) is an approach that
takes into account both the clinical evidence for treat-
ment goals as well as the patient’s preferences. SDM is
defined as ‘an approach where clinicians and patients
make decisions together, using the best available evi-
dence’ [17]. It promotes patient autonomy and patient
engagement in the treatment decision making by giving
the patient an active role in weighting the benefits and
harms of more than one evidence based treatment op-
tion [17]. Although SDM is promising for patients with
chronic diseases by setting realistic treatment targets,
such an extensive approach had not been broadly stud-
ied in T2DM patients before 2008 [18]. Recently the ef-
fects a patient oriented decision aid for SDM and goal
setting in T2DM patients on patient empowerment and
treatment decisions have been published [19]. No effect
was found on empowerment, the decision aid was notused to measure the effect on clinical outcomes and
achievement of goals.
Because SDM is especially useful when there are two
or more equally beneficial treatment options, the results
of the ADDITION-Europe study, in which the Netherlands
participated, could be used in a SDM approach in patients
with T2DM. The ADDITION study included screen de-
tected T2DM patients and compared an intensive multi-
factorial treatment of HbA1c, cholesterol, blood pressure
and body weight with less intensive usual care according to
national guidelines. The intensive treatment was associated
with a significant increase in prescribed medications and a
non-significant 17% reduction of cardiovascular events and
death after 5 years. However, the rate of cardiovascular
events seemed to diverge after 4 years of follow-up. It was
concluded that intensified treatment and treatment ac-
cording to national guidelines can theoretically be equally
effective [1]. Based on the results of the ADDITION study,
it is questionable which evidence based treatment advice
the diabetes care provider should give to the T2DM pa-
tient. There is no decisive evidence for either option. This
situation is very appropriate for treatment decisions that
incorporate the patient’s preferences.
In a recent statement of both the American Diabetes
Association (ADA) and the European Association for
the Study of Diabetes (EASD) personalised and patient-
centred care is mentioned as the cornerstone of the
treatment of patients with T2DM. The use of a decision
support tool is strongly advocated [8]. A decision sup-
port tool can encourage active patient participation in
many evidence-based healthcare decisions [20-22]. In
the last decade decision support tools have been devel-
oped to support the achievement of cardiometabolic
goals and to select patient-centred treatment options for
lifestyle modifications or medication use [8,23-28]. How-
ever, most of them focus on a single risk factor [25], on
only the patients’ preferences [26,27] or on some indi-
vidual clinical characteristics [28]. We hypothesise that a
decision support tool that takes into account both treat-
ment intensity, patient’s clinical characteristics and pa-
tient’s preferences can facilitate a SDM process and will
be effective in achieving treatment targets. We aim to
evaluate whether such an approach increases the propor-
tion of treatment targets that T2DM patients achieve.
The following research questions are addressed:
1. What is the effect of shared decision making with a
multi-faceted decision support tool on the percentage
of patients with T2DM that achieve all individualised
treatment targets for HbA1c, blood pressure and
LDL-cholesterol; and to identify determinants for
achieving all individualised treatment targets.
2. What is the effect of shared decision making with a
multi-faceted decision support tool on treatment
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and on coping styles?
3. What is the level of SDM-knowledge/attitude of the
GPs from both treatment groups after 24 months?
Methods
Study design and setting
The OPTIMAL study is a cluster-randomised trial with
randomisation at practice-level and two years follow-up.
We developed an intervention to promote SDM with a
decision support tool based on the results of the above
mentioned ADDITION-Europe study. Since for an opti-
mal SDM approach physicians should have some experi-
ence with all treatment options, patients are recruitedFigure 1 Flow chart.from the 79 general practices that participated in the
ADDITION study [29]. For the OPTIMAL study prac-
tices are randomised again (Figure 1). GPs in the inter-
vention group were trained in SDM (see further).
Practices and patients
Eligible GPs are those who included at least included
one patient in the ADDITION-study. For the OPTIMAL
study each GP should include at least two more or less
comparable patients: 1. Former ‘ADDITION’ patients di-
agnosed with T2DM in 2002-2004 by screening, aged
between 50-70 years at that time and having participated
in the ADDITION study that ended in 2009; 2. Patients
between 60 and 80 years in 2012-2014, known with type
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ADDITION study. Patients will be excluded if they have
a history of alcoholism, drug abuse, psychosis, personal-
ity disorder or another emotional, psychological or intel-
lectual problem that is likely to invalidate informed
consent, or limit the ability of the individual to comply
with the protocol requirements. Also, patients with a
limited life expectancy will not be approached.
Randomisation
Randomisation is executed at the research center at
practice-level, without any stratification. It is not pos-
sible to blind participants and GPs for the treatment al-
location. Practices are randomised a second time, i.e.
intervention practices in the ADDITION study could be
control practices in the current study and vice versa.
Intervention
1. The decision support tool.Figure 2 Decision support tool.The OPTIMAL decision support tool is a simple
paper-based tool, aimed to be easy to use for both
the GP and the patients. It should be used to discuss
the treatment options and the prioritising of treatment
targets during the first visit and the 12- and 24-months
follow-up visits. The tool consists of three steps:
1) considering the pros and cons of two almost equally
effective evidence based multifactorial treatments,
namely the intensified ADDITION protocol and the
protocol derived from the 2006 Dutch guidelines for
GPs [1] (for details see Figure 2, step 1b), and the
shared decision on which option will be chosen;
2) prioritising of treatment targets according to the
chosen option, and 3) treatment selection (medication
or lifestyle) to achieve the treatment targets. For
detailed information about the two treatment options
and the different targets see Figure 2.
2. Visits during the OPTIMAL study.
During the first visit, and guided by the decision tool,
the GP and the patient discuss the two evidence based
T2DM treatments. The GP will explain the pros and
cons of each option, and the treatment targets that
should be achieved, depending on the option that is
chosen. The GP should explain that both treatments
are equally suitable for treating T2DM. Next, the
patient’s preferences and lifestyle habits are discussed
against the background of the patient’s most recent
values of HbA1c, lipids, blood pressure, body weight
and smoking habits. Then the GP and the patient will
together decide on the preferred treatment option and
the accompanying treatment targets. For a patient
who underwent the intensified treatment in the
ADDITION study and did not change it after the end
of ADDITION, this visit provides him/her the
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the other way around is possible. The patient will
prioritise the five treatment targets (HbA1c,
cholesterol, blood pressure, body weight, smoking
habits) for the first 12 months. The target with the
highest priority will get the most attention and
require the most effort of both the patient and GP.
There will be no pre-defined way in how the patients
should reach their targets; the patient and the GP
need to determine this way together in a final step in
the decision process. The patient and GP decide
whether medication changes and/or lifestyle changes
should be made in order to reach the prioritised
targets. During the second and third OPTIMAL
visit (12 and 24 months later) the patient and GP
evaluate the decisions they made during the first
visit using the decision support tool. The priority of
the treatment targets can be changed during these
visits, but not the choice between the two treatment
options (ADDITION protocol or the less intensive
protocol). During the third and final visit the patient
and the GP will decide whether or not to keep to
the chosen treatment option. Between the first and
third visit, three monthly T2DM visits will take
place either with the GP or the practice nurse.Training
The GPs from the practices randomised to the SDM-
treatment arm are trained in the SDM approach during
a two hours training session. During this session the
study protocol is discussed as well as the SDM principle
(see further) and the OPTIMAL decision support tool.
By use of role-plays the SDM process will be practiced
by the GPs.
Control group
Patients in the control practices will receive
treatment-as-before. Also, the GPs will not be asked
to engage in a SDM process, nor be trained to do
this and they will not be offered the decision sup-
port tool. The GP will treat the patients as they
were used to since the ending of the ADDITION
study (2009), either following the national guidelines
or the ADDITION intensive treatment algorithm,
each with their respective targets [1].
Outcome measures
Primary outcome will be the proportion of patients that
achieve all the three treatment goals for HbA1c, blood
pressure, and total cholesterol .In addition to identify de-
terminants of better performing patients for the primary
outcome will be performed taken into account the inter-
action of SDM with age, gender, education level, dur-
ation of diabetes and comorbidities.Secondary outcomes:
 The proportion of patients that achieve the all five
treatment goals for HbA1c, blood pressure, total and
LDL- cholesterol, body weight, and smoking.
 The following patient reported outcomes: diabetes
treatment satisfaction, perceived quality of life,
health status, well-being, and coping style.
 A process evaluation of the shared decision making
ability of the general practitioners during the
complete study. Outcome on GP level: the level of
SDM-knowledge/attitude.
Measurements, data collection
Data about the patient’s socio-demographic background,
the level of education, smoking status and whether the pa-
tient lives alone or together will be collected by patients’
self-report at baseline. HbA1c, blood pressure, body weight,
total cholesterol and LDL-cholesterol, and smoking habits
as well as patient characteristics (age, gender, duration of
diabetes and comorbidities) will be reported every year by
the GPs on a specific Case Report Form in both groups.
Blood pressure is measured by two measurements after
at least 10 minutes rest, while participants are seated with
the cuff on the predominant arm at the level of the heart,
using an automatic sphygmomanometer. Height and body
weight are measured in light indoor clothing and without
shoes using a fixed rigid stadiometer and a scale respect-
ively. Laboratory results (HbA1c, LDL-cholesterol) were
obtained with case report from the GPs electronic records.
Participants in both groups will be asked to complete
and return the following questionnaires baseline and
after 24 months at home.
a) the Diabetes Treatment Satisfaction Questionnaire
(DTSQ) [30] which includes 8 items; scores range
from 0 (very dissatisfied) to 6 (very satisfied), totally
from 0 to 48. The DTSQ is reliable, valid and
sensitive to change in diabetes patients [30];
b) the Audit of Diabetes Dependent Quality of Life
(ADD QoL-19), which measures the perceived
impact of diabetes on the quality of life; it includes
19 items, ranging from -3 to 3 on different questions,
with 0 as the neutral score. Scores below 0 reflect a
negative influence of the item on quality of life, and all
above 0 reflect positive influences. The impact scores
are weighted (impact rating x importance rating), so
the actual scores per item can range from -9 to 9. The
ADDQoL-19 has good psychometric properties and
provides clinicians and researchers with a useful tool
for comprehensively assessing quality of life in adults
with T2DM [31];
c) the Well-Being Questionnaire (W-BQ12) that
consists of 12-items in three 4-item subscales:
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greater sense of negative well-being), energy (items
6 and 7 are reversed, and then together with 5 and 8
form the total amount of energy) and positive
well-being (items 9-12, the higher the score the
greater the sense of positive well-being). The total
score ranges from 0 to 36 and is called the general
well-being score. Higher scores indicate a higher
overall sense of well-being [32];
d) the European Quality of Life (EQ-5D) questionnaire,
that covers 5 dimensions (mobility, self-care, usual
activities, pain/discomfort and anxiety/depression)
and a Visual Analogue Scale (VAS) where respondents
can rate their health. Item scores range from 1-3, and
a 5-digit health profile is formed, placing the 5
numbers behind each other. It is a well-validated,
reliable and responsive instrument for health
measurement in patients with a wide range of medical
conditions. Values found in the UK have been
validated for the Netherlands [33-35];
e) the Short Form-36, a validated 36-item instrument
for the self-evaluation of health status with eight
subscales: Physical Functioning (10 items), Role
Physical (4 items), Bodily Pain (2 items), General
Health (5 items), Vitality (4 items), Social Functioning
(2 items), Role-Emotional (3 items) and Mental
Health (5 items). These scales can be summarised in
Physical Health and Mental Health. The 36 items
differ in the scoring ranges. The Dutch version has
proved to be a practical, reliable and valid
instrument [36,37];
f ) the Diabetes Coping Measurement Questionnaire
(DCMQ), consisting of 21 items in 4 subscales: spirit
coping, avoidance coping, passive resignation coping
and diabetes integration coping. Overall scores range
from 7 to 35. The items are measures on a 5-point
Likert scale, ranging from 1 (“disagree”) to 5 (“agree
strongly”) or the other way around from 1 (‘I strongly
agree’) to 5 (I ‘disagree’). Higher scores on tackling
spirit and diabetes integration indicate more adaptive
coping. Higher scores on passive resignation and
avoidance indicate poor coping [38].
A process evaluation of the shared decision making
ability of the general practitioners will be measured in
the intervention group at baseline and after 12 months,
and in both treatment groups at 24 months. Both the
patients and GPs will be asked to complete The Shared
Decision Making Questionnaire, both the patient (SDM-
Q9-patient) and GP (SDM-Q9-doc) version will be used
to evaluate this process.
The Shared Decision Making Questionnaire (both
SDM-Q9 versions) [39-41] includes 9 items with ratings
from 0 (completely disagree) to 6 (completely agree); thetotal score ranges from 0 to 54. It is a continuous scale,
and the questionnaire developers did not describe any
thresholds for ‘bad’ or ‘good’ SDM. Over the last years
the SDM-Q9 has become a frequently used instrument
in clinical practice. It has been translated into several
languages. Internal consistency has been assessed for the
Spanish and Dutch version (Rodenburg-Vandenbussche
S, Pieterse AH, Kroonenberg PM, Stiggelbout AM,et al.:
Further validation of the SDM-Q-9 and SDM-Q-Doc:
psychometric properties in Dutch patients from primary
and secondary care. Submitted). Item discrimination pa-
rameters were above 0.4 for all but one item. An analysis
of internal consistency yielded a Cronbach’s α of 0.88
[39]. The Dutch version is currently being validated [41].
A modified version of the Control Preferences Scale
(CPS) is used to determine the experienced role of deci-
sion making of the GP and patient. The CPS measures at
a 5-point Likert scale, and has shown good reliability and
validity [41,42]. The original Control Preference Scale by
Degner [41], was developed to measure preference for in-
volvement and is one of the most commonly used instru-
ments to assess preferred decisional role [41,42].
Subsequently, the GPs of both groups (the interven-
tion group trained, the control group not) will audio- or
videotape one of their yearly consultations with a T2DM
patient. They can choose the consultation to be taped
themselves. These tapes will be evaluated by two inde-
pendent observers, making use of the SDM-Q9, to assess
the extent to which the GP is likely to involve his/her
patients in the diabetes treatment.
Sample size
As stated in the Introduction, only 10-15% of T2DM pa-
tients achieve all three treatment targets for both
HbA1c, lipids and blood pressure. We estimate the per-
centage of patients that already has reached three targets
at the start of the study will be approximately 10%. We
hypothesise that in the OPTIMAL study, after two years
of follow-up, the intervention group will show an in-
crease of this percentage until 30% (about 10% increase
per year), whereas in the treatment-as-before-group this
percentage will stay at 10%. Assuming a two-sided sig-
nificance level of 5%, with alpha 0.05 and power of 80%
and with a drop-out of 10%, 65 patients will be needed
in each treatment group (Department of Statistics Sam-
ple Size Calculator, University of British Columbia). Be-
cause the OPTIMAL study is a cluster randomised study
the sample size will require an correction for the cluster
effect. The used correction factor is equal to [1 + (m - 1) r],
where ‘m’ is the total amount of eligible patient per prac-
tice (approximately 6), and ‘r’ the within-cluster correlation
coefficient. For ‘r’ we use a within-cluster correlation coef-
ficient of 0.025, based on the cluster correlation found in
the ADDITION-Europe study. When taken the cluster
den Ouden et al. BMC Family Practice  (2015) 16:27 Page 7 of 8effect (1.125) in to account, 73 patients per group are
needed.
Statistical analyses
Intention-to-treat analyses (ITT) will be performed to
examine between-group differences. Generalized linear
models will be used to correct for clustering at practice
level. The proportions of achieved treatment goals of
HbA1c, blood pressure, LDL-cholesterol within each
study group will be estimated by calculating relative risk.
The same applies to the difference between groups in
the proportion of patients which achieved all the five
above mentioned treatment goals. A p-value of <0.05 is
considered statistically significant. To identify patients
who show better results after the SDM process, the ana-
lysis for the primary outcome will be repeated with
taken into account interaction of SDM with age, gender,
education level, duration of diabetes and comorbidities.
Within and between group differences in treatment sat-
isfaction, perceived quality of life, health status, well-
being, and coping style between baseline and 24 months
follow-up will be analysed by using paired t-tests and
mixed models respectively. We will add random effects
for patient and practice.
The SDM-Q9 will be analysed in the intervention
group by using paired t-tests. Mixed models will be used
to study the between groups differences after 24 months.
We will add random effects for patient and practice.
To evaluate the SDM proces, the tapes will be evalu-
ated by two independent observers by making use of the
SDM-Q9.
The Medical Research Ethics Committee of the University
Medical Centre Utrecht has approved the study protocol
(Protocol number: 11-153).
Discussion
The treatment of T2DM is mostly target driven. How-
ever, only a low percentage of all patients with T2DM
achieve all goals. SDM and goal setting can be useful to
increase the percentage of patients that achieve all tar-
gets. However, the decision support tool to be used in
SDM should likely not only focus on the clinical factors
of the patients but also on the patient’s preferences, be-
cause each of these variables may affect the optimal treat-
ment targets. Besides, the decision support tool should be
used in a SDM process during more than one consultation
[8]. The results of the ADDITION trial, in which half
of the participants of the current study also participated,
offers a unique opportunity to discuss with the patient
two almost equally effective treatment strategies.
In the current cluster-randomised controlled trial we
will evaluate the effectiveness of such a repeated use of a
decision support tool, taking into account both the in-
tensity of treatment, individual clinical factors and thepatients’ experiences and preferences. We hypothesise
that the SDM process with such a well-balanced decision
support tool will improve the percentage of patients that
achieve all three individual goals compared to the con-
trol group, making SDM really beneficial.
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